CAS, an American Chemical Society division specializing in scientific information solutions, and Mana.bio, creating an AI-driven drug delivery platform for gene therapy, announced an agreement to embed chemical substance data from the CAS Content Collection™ directly into the Mana.bio AI data acquisition workflow via a application programmable interface (API). This collaboration will enrich Mana.bio's proprietary database fuels its AI engine, with an expected 70% reduction in resources allocated to molecular data acquisition and preparation.
Mana.bio is focused on developing novel drug delivery solutions for gene therapy and vaccines, using artificial intelligence and machine learning capabilities.
The CAS Content Collection covers scientific advances over the last 150 years in over 50 languages from journal and patent publications. It includes references, chemical substances, proteins, reactions, physical and chemical properties, formulations, bioactivity data, and more. Sourced, curated, and connected by a team of hundreds of scientists, it is the world's largest and highest quality collection of human-curated scientific information. The CAS Custom Services team works with organizations globally to design custom solutions that drive discovery.
Click here to read the original press release.
More News in this Theme
